Phase 3 study of PET cardiac imaging agent flurpiridaz F 18 shows diagnostic accuracy while reducing radiation exposure.

May 5, 2015

Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents and products, today announced that results from its first Phase 3 study of flurpiridaz F 18 for myocardial perfusion imaging (MPI) were presented at the International Conference on Nuclear Cardiology and Cardiac CT (ICNC12) in Madrid, Spain.

The oral presentation, "Flurpiridaz F 18 MPI: Recent clinical trial data," was made by Jamshid Maddahi, M.D., Professor of Medicine (Cardiology) and Molecular & Medical Pharmacology (Nuclear Medicine), David Geffen School of Medicine at UCLA, in the "Important Clinical Trials and Registries in Nuclear Cardiology" session of ICNC12. "Analysis of the first Phase 3 clinical study has confirmed the value of this novel agent as compared with standard SPECT imaging for the diagnosis of coronary artery disease," said Dr. Maddahi, the Principal Investigator of the study.

Full Story